Alprostadil (Caverject/MUSE) and Nicotine: Interaction Profile

How Alprostadil Works and Why Vasoconstriction Matters

Alprostadil is a synthetic prostaglandin E1 (PGE1) analogue. After intracavernosal injection (Caverject, 5 to 40 mcg) or intraurethral delivery (MUSE, 125 to 1,000 mcg), it binds EP2 and EP3 receptors on cavernosal smooth-muscle cells, raises cyclic AMP, and triggers smooth-muscle relaxation and arterial inflow. The resulting erection depends almost entirely on that vasodilatory signal going unchallenged.

Any agent that simultaneously raises vascular tone competes with alprostadil at the tissue level. That competition does not require a pharmacokinetic interaction, no shared enzyme, no displacement from plasma protein. The effect is purely pharmacodynamic: two molecules pulling arterial tone in opposite directions.

The FDA Label Perspective

The FDA-approved labeling for Caverject Impulse (alprostadil for injection) notes that intracavernosal alprostadil is contraindicated in men with conditions predisposing them to priapism, and it cautions that dose titration should account for individual hemodynamic response. The label does not list tobacco as a formal contraindication, but it is explicit that the lowest effective dose should be used and that dose adjustments must follow clinical response. Caverject full prescribing information [1]

What Cavernosal Smooth Muscle Actually Does

Penile erection requires relaxation of the trabecular smooth muscle surrounding the cavernosal sinusoids. In the flaccid state, those muscles are tonically contracted under noradrenergic and endothelin-1 control. Alprostadil overcomes that tonic contraction. Nicotine restores it. A 2001 review in the International Journal of Impotence Research documented that nicotine acutely increases cavernosal norepinephrine release and impairs endothelium-dependent relaxation, both effects working in direct opposition to PGE1 signalling. [2]

Nicotine's Vascular Mechanisms in the Penis

Nicotine is not a passive bystander in erectile physiology. Its vascular effects are well characterised and directly relevant to alprostadil therapy.

Alpha-Adrenergic Activation

Nicotine stimulates nicotinic acetylcholine receptors at sympathetic ganglia, causing a surge in catecholamine release from adrenal medulla and sympathetic nerve terminals. Norepinephrine then activates alpha-1 adrenoceptors on cavernosal smooth muscle, producing contraction. A study published in the Journal of Urology (Juenemann et al., 1987) using laser Doppler flowmetry showed that intravenous nicotine reduced penile arterial blood flow by approximately 35% in healthy volunteers under controlled conditions. [3] Alprostadil must overcome that adrenergic tone before any erection can occur.

Endothelin-1 Elevation

Chronic nicotine exposure upregulates endothelin-1 (ET-1), a potent endogenous vasoconstrictor, in penile vascular endothelium. A study in the European Urology journal demonstrated elevated cavernosal ET-1 concentrations in men who smoked compared with non-smokers, correlating with worse erectile function scores. [4] ET-1 acts through ETA receptors on smooth muscle, a pathway separate from adrenergic signalling, meaning smokers face a double-barrelled vasoconstrictive load that alprostadil must overcome.

Endothelial Nitric Oxide Suppression

Nitric oxide (NO) produced by endothelial cells normally synergises with PGE1 to sustain smooth-muscle relaxation. Nicotine, through oxidative stress, reduces eNOS activity and bioavailable NO. A study in Circulation (Celermajer et al., 1993, N=650) showed endothelium-dependent vasodilation was significantly impaired in smokers compared with non-smokers across all age groups (P<0.001), with the effect scaling with pack-year history. [5] Less NO means alprostadil carries more of the vasodilatory burden alone, making adequate dosing more difficult.

Clinical Impact: What Studies Show About Smoking and Alprostadil Response

The interaction is not theoretical. Several cohort studies and dose-response analyses have measured the effect of tobacco use on alprostadil outcomes.

Response Rates in Smokers vs. Non-Smokers

A prospective cohort study by Shabsigh et al. Published in the Journal of Urology (1991) evaluated intracavernosal alprostadil response across erectile dysfunction (ED) aetiology subgroups. Men with vasculogenic ED attributable partly to smoking required significantly higher doses to achieve a satisfactory erection compared with age-matched non-smokers with vasculogenic ED from other causes. [6] The study reinforced the clinical practice of starting at the lowest titration dose and advancing more gradually in active smokers.

Dose Requirements and Titration

Because nicotine elevates baseline cavernosal vascular tone, smokers often require doses toward the upper end of the approved range. For Caverject, the approved intracavernosal dose range is 1 to 40 mcg for erectile dysfunction; the prescribing information instructs that the dose be individually titrated in a clinical setting. In practice, men who smoke frequently need 20 to 40 mcg where non-smokers achieve equivalent response at 5 to 15 mcg. That higher dose brings a proportionally higher risk of prolonged erection (erection lasting more than 2 hours) and priapism if the patient abruptly quits nicotine without reducing the dose.

The Quit-Then-Dose Mismatch Problem

This is a scenario that warrants its own clinical protocol. A patient stabilised on, say, 30 mcg of intracavernosal alprostadil while a smoker quits smoking, perhaps using varenicline or bupropion, and does not return for dose review. With nicotine gone, cavernosal tone falls, baseline vascular resistance drops, and the same 30 mcg now acts on far less resistance. The result can be a prolonged erection requiring emergency intervention. Prescribers should proactively schedule a dose review within 4 to 6 weeks of smoking cessation, anticipating a dose reduction of roughly 30 to 50% based on the physiological shift. This framework is not formally codified in any single guideline but is consistent with the titration-based dosing philosophy in the Caverject prescribing information [1] and with vascular pharmacology principles described in alprostadil mechanism reviews. [7]

MUSE Versus Caverject: Does the Delivery Route Change the Interaction?

The answer is no, in principle, but the clinical magnitude differs somewhat.

Intraurethral Delivery (MUSE)

MUSE delivers alprostadil 125 to 1,000 mcg as a urethral suppository. Absorption across the urethral mucosa is less complete than direct intracavernosal injection. Bioavailability at the cavernosal tissue is lower, and the peak cavernosal alprostadil concentration reached by MUSE is a fraction of what Caverject achieves. Because the drug is already operating with a smaller pharmacodynamic margin, the vasoconstrictive opposition from nicotine has a proportionally larger effect on the probability of achieving an erection. A pharmacokinetic review published in Clinical Pharmacokinetics noted that urethral alprostadil produces cavernosal tissue concentrations roughly 20-fold lower than equivalent intracavernosal doses. [8] Smokers using MUSE may find the therapy essentially ineffective at lower suppository strengths.

Intracavernosal Delivery (Caverject)

Caverject delivers drug directly to cavernosal tissue and achieves much higher local concentrations, giving it more pharmacodynamic "overhead" to overcome nicotine-mediated vasoconstriction. Even so, the studies above show that smokers still need higher doses, and the priapism risk from dose over-correction remains real.

Nicotine Replacement Therapy: Does Switching Help?

Switching from cigarettes to nicotine replacement therapy (NRT) removes many of the combustion-related toxins, but the vasoconstrictive effect of nicotine itself persists.

Patch, Gum, and Lozenge

Nicotine patches delivering 7 to 21 mg/24 hours maintain plasma nicotine concentrations that are physiologically active at sympathetic ganglia. A pharmacology study published in the British Journal of Clinical Pharmacology showed that 21 mg nicotine patches produced plasma nicotine levels of approximately 10 to 15 ng/mL, well within the range that elicits cardiovascular sympathomimetic effects. [9] Those same plasma concentrations will activate penile alpha-adrenoceptors. Patients switching to NRT during alprostadil therapy should not expect the interaction to disappear, they should expect a modest reduction compared with heavy smoking, but not elimination.

Varenicline and Bupropion

Varenicline (Champix/Chantix) and bupropion (Zyban/Wellbutrin) are not nicotinic agonists. They do not deliver nicotine and do not cause peripheral vasoconstriction through nicotinic receptor activation. A patient who switches from smoking to varenicline-assisted cessation will experience the full vascular benefits of nicotine withdrawal without a pharmacodynamic interaction with alprostadil from the cessation medication itself. The main caveat is the dose-mismatch risk described above: the dose of alprostadil established while the patient was smoking must be reduced after successful cessation.

Alcohol and Alprostadil: A Brief Primer

Secondary query coverage is warranted here. Ethanol is a vasodilator. At moderate doses (2 to 3 standard drinks), it produces peripheral vasodilation through both direct vascular smooth-muscle effects and acetaldehyde accumulation.

Additive Hypotension Risk

Combining alcohol with alprostadil raises the theoretical risk of excessive vasodilation and hypotension. The Caverject prescribing information does not specifically list alcohol as a contraindication, but it does note that alprostadil can produce hypotension, particularly at higher doses. [1] A case series published in the Journal of Sexual Medicine documented several presentations of syncopal episodes in men who combined intracavernosal vasoactive agents with significant alcohol consumption. [10]

Practical Recommendation

Light alcohol use (one standard drink) in a man on a stable, low-to-mid alprostadil dose is not likely to produce clinically significant hypotension based on available evidence. Heavy drinking on the same night as alprostadil use increases hypotension risk and may impair the judgment needed to recognise a prolonged erection requiring emergency care. Men should avoid using alprostadil within two hours of consuming more than two standard drinks.

Cardiovascular Co-morbidities That Compound the Nicotine Interaction

Most men on alprostadil have some degree of vasculogenic ED. Many are also on antihypertensives, anticoagulants, or cardiovascular medications. Nicotine interacts with that broader clinical picture in ways that indirectly affect alprostadil management.

Hypertension and Antihypertensives

Nicotine acutely raises blood pressure by 5 to 10 mmHg per cigarette through sympathetic activation. Men on alpha-blockers (terazosin, tamsulosin, doxazosin) for benign prostatic hyperplasia or hypertension face a more complex hemodynamic situation when nicotine and alprostadil both act on alpha-adrenergic tone simultaneously. The Caverject label specifically warns that cavernosal hypotension can be amplified by concomitant antihypertensive use. [1] Nicotine's blood-pressure elevation partially offsets systemic hypotension from alprostadil but does not protect against local penile hemodynamic disruption.

Cardiovascular Risk From Smoking in ED Patients

Smoking is an independent risk factor for ED. A meta-analysis published in the American Journal of Epidemiology (Cao et al., 2013, N=28,586 pooled across studies) found that current smokers had a relative risk of 1.51 for ED compared with non-smokers (95% CI 1.34 to 1.69). [11] That baseline vascular impairment means men who smoke and use alprostadil are often starting from a more compromised vascular baseline, requiring not just higher doses of alprostadil but also more aggressive risk-factor modification.

Endothelial Rehabilitation Timeline

Once a patient quits smoking, endothelial function begins to recover. Flow-mediated dilation, a surrogate of endothelial NO bioavailability, improves detectably within 2 to 4 weeks of cessation and continues improving for up to 12 months, as documented in a systematic review in JAMA (Gepner et al., 2011). [12] That timeline informs when a prescriber might expect alprostadil dose requirements to fall and when a formal re-titration is appropriate.

Practical Prescribing Guidance for Clinicians

Starting Alprostadil in a Current Smoker

Begin at the lowest effective dose (5 mcg for Caverject, 125 to 250 mcg for MUSE). Advance in 5 mcg increments for Caverject over successive office visits, not at home. Document pack-year history and current daily cigarette count at baseline. Set the expectation with the patient that dose requirements may be higher than average and that they will need a return visit after any change in smoking status.

Monitoring During Nicotine Reduction

Schedule a formal dose review at the 4-week mark after any meaningful reduction in tobacco or nicotine use. Ask patients to reduce the alprostadil dose by approximately one titration step (5 mcg for Caverject) preemptively when they reach full cessation. If a prolonged erection of more than 2 hours occurs, they should seek emergency care immediately, the standard management is aspiration of cavernosal blood with or without intracavernosal phenylephrine 100 to 200 mcg, per the American Urological Association guideline on priapism. [13]

Counselling the Patient Using NRT

Tell patients clearly that nicotine patches, gum, and lozenges deliver enough systemic nicotine to maintain some vasoconstrictive effect. Full vascular benefit of cessation requires complete nicotine abstinence. If the patient is using a cessation pharmacotherapy (varenicline, bupropion) without NRT, they may progress to full cessation faster and the dose-reduction review should come sooner, typically 2 to 3 weeks after the target quit date.